Immunotolerance induction in a pediatric hemophilic patient in Costa Rica

Autores/as

  • Adriana Porras Moreno
  • Danny Ugalde Solera

DOI:

https://doi.org/10.51481/amc.v60i3.1010

Resumen

Hemophilia A is an X – linked bleeding disorder. It can be treated with Factor VIII prophylaxis or on demand treatment. Most countries in the world use prophylaxis as it is less expensive than treating patients when they are bleeding. The production of factor VIII inhibitors is the most common and serious complication of the treatment. Immune tolerance induction (ITI) is the only option of treatment when patients develop inhibitors proven to be successful to eradicate this condition, therefore decreasing inhibitors and costs. A case of a successful immune tolerance induction with low doses of factor VIII (FVIII) in a pediatric patient with severe hemophilia A and FVIII inhibitors is presented. Even though inmunotolerance has been practice before in our country, a case like this has never been published.

Descargas

Publicado

2018-07-27 — Actualizado el 2020-07-16

Versiones

Cómo citar

Moreno, A. P., & Solera, D. U. (2020). Immunotolerance induction in a pediatric hemophilic patient in Costa Rica. Acta Médica Costarricense , 60(3). https://doi.org/10.51481/amc.v60i3.1010 (Original work published 27 de julio de 2018)